Universal prevention of schizophrenia and surrogate endpoints at population level.
Despite significant progresses in our knowledge of the risk factors for schizophrenia, we still are several steps short of implementing effective prevention strategies. Universal prevention strategies have several theoretical advantages but their implementation has been limited to date by their costs and lack of methods to assess their efficiency. To overcome this limitation, we suggest, based on research from therapeutic trials at individual level, the use of surrogate endpoints (SEs) at population level. We further suggest that subclinical measures of psychosis at population level are good SEs candidates for assessing universal measures for schizophrenia prevention.
AP-HP, Groupe Hospitalier "Mondor", Pôle de Psychiatrie, Créteil, 94000, France, andrei.szoke@inserm.fr.
A
A
Szöke
J B
JB
Kirkbride
F
F
Schürhoff
D015415:Biomarkers; D006801:Humans; D012307:Risk Factors; D012559:Schizophrenia / Q000453:epidemiology / Q000517:prevention & control*
D015415:Biomarkers